44 results on '"Topkan, Erkan"'
Search Results
2. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy.
- Author
-
Topkan E, Kucuk A, Ozturk D, Ozkan EE, Besen AA, Pehlivan B, and Selek U
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Aged, Prognosis, Neoplasm Staging, Serum Albumin analysis, Weight Loss, Adult, ROC Curve, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung mortality, Lung Neoplasms therapy, Lung Neoplasms pathology, Lung Neoplasms mortality, Chemoradiotherapy methods, C-Reactive Protein analysis
- Abstract
Objectives: We explored the prognostic utility of the unique combination of C-reactive-protein-to-albumin ratio (CAR) and significant weight loss (WL > 5%) over the preceding 6 months, namely, the CARWL score, in stage IIIC non-small-cell lung cancer (NSCLC) patients who underwent concurrent chemoradiotherapy (CCRT)., Methods: For each patient, the CAR was calculated using C-reactive protein and albumin measurements obtained on the first day of CCRT: CAR = C-reactive protein ÷ albumin. The availability of an ideal CAR cutoff that may categorize patients into two distinct progression-free (PFS) and overall survival (OS) outcomes was explored by employing receiver operating characteristic (ROC) curve analysis. Patients were additionally divided into two groups based on their status of significant WL according to the well-recognized Delphi criteria. Then, the CARWL score was created by combining all feasible combinations of the CAR and significant WL groupings. The potential links between pretreatment CARWL groups and the post-CCRT OS and PFS outcomes were determined as the primary and secondary endpoints., Results: This retrospective cohort study comprised a total of 651 stage IIIC NSCLC patients. ROC curve analysis indicated that rounded 3.0 was the ideal CAR cutoff (area under the curve (AUC): 70.1%; sensitivity: 67.8%; specificity: 65.9%), which categorized the patients into CAR < 3.0 ( N = 324) and CAR ≥ 3.0 ( N = 327) groups. There were 308 (47.3%) and 343 (52.7%) patients without and with significant WL, respectively. The created CARWL groups were CARWL-0: CAR < 3.0 and WL ≤ 5.0%; CARWL-1: CAR < 3.0 and WL > 5.0%, or CAR ≥ 3.0 and WL ≤ 5.0%; and CARWL-2: CAR > 3.0 and WL > 5.0%. The Kaplan-Meier curves showed that the PFS (14.2 vs. 11.4 vs. 7.5 months; P < 0.001) and OS (37.3 vs. 23.6 vs. 12.8 months; P < 0.001) durations were gradually and significantly lowered from the CARWL-0 to CARWL-2 groups. The CARWL score's significant impacts on PFS and OS outcomes were found to be independent of the other variables in the multivariate analysis ( P < 0.001, for each)., Conclusions: Our findings indicate that the novel CARWL score, which accounts for pretreatment CAR and significant WL during the preceding 6 months, can reliably stratify newly diagnosed stage IIIC NSCLC patients into three groups with significantly different PFS and OS after definitive CCRT., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2024 Erkan Topkan et al.)
- Published
- 2024
- Full Text
- View/download PDF
3. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients.
- Author
-
Somay E, Topkan E, Kucuk A, Ozturk D, Ozkan EE, Ozdemir BS, Besen AA, Mertsoylu H, Pehlivan B, and Selek U
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Platelet Count, Adult, Aged, Jaw Diseases diagnosis, Jaw Diseases epidemiology, Jaw Diseases therapy, Jaw Diseases etiology, Incidence, Predictive Value of Tests, Osteoradionecrosis etiology, Osteoradionecrosis diagnosis, Osteoradionecrosis epidemiology, Osteoradionecrosis therapy, Nasopharyngeal Carcinoma therapy, Nasopharyngeal Carcinoma diagnosis, Nasopharyngeal Carcinoma pathology, Chemoradiotherapy adverse effects, Nasopharyngeal Neoplasms therapy, Nasopharyngeal Neoplasms diagnosis, Nasopharyngeal Neoplasms blood
- Abstract
Introduction: This retrospective study aimed to investigate if pretreatment platelet (PLT) levels can predict the risk of osteoradionecrosis of the jaw (ORNJ) in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) who received concurrent chemoradiotherapy (CCRT)., Material &methods: ORNJ instances were identified from LA-NPC patients' pre- and post-CCRT oral exam records. All pretreatment PLT values were acquired on the first day of CCRT. Receiver operating characteristic curve analysis was used to determine the optimal PLT cutoff that divides patients into two subgroups with distinctive ORNJ rates. The primary outcome measure was the association between pretreatment PLT values and ORNJ incidence rates., Results: The incidence of ORNJ was 8.8 % among the 240 LA-NPC patients analyzed. The ideal pre-CCRT PLT cutoff which divided the patients into two significantly different ORNJ rate groups was 285,000 cells/µL (PLT ≤ 285,000 cells/µL (N = 175) vs. PLT > 285,000 cells/µL (N = 65)). A comparison of the two PLT groups revealed that the incidence of ORNJ was substantially higher in patients with PLT > 285,000 cells/L than in those with PLT≤285,000 cells/L (26.2% vs. 2.3 %; P < 0.001). The presence of pre-CCRT ≥3 tooth extractions, any post-CCRT tooth extractions, mean mandibular dose ≥ 34.1 Gy, mandibular V57.5 Gy ≥ 34.7 %, and post-CCRT tooth extractions > 9 months after CCRT completion were also associated with significantly increased ORNJ rates. A multivariate Cox regression analysis demonstrated that each characteristic had an independent significance on ORNJ rates after CCRT., Conclusion: An affordable and easily accessible novel biomarker, PLT> 285,000 cells/L, may predict substantially higher ORNJ rates after definitive CCRT in individuals with LA-NPC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Low hemoglobin levels predict increased radiation-induced trismus rates in nasopharyngeal cancer.
- Author
-
Somay E, Yilmaz B, Topkan E, Pehlivan B, and Selek U
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Radiation Injuries blood, Radiation Injuries etiology, Nasopharyngeal Carcinoma radiotherapy, Nasopharyngeal Carcinoma blood, ROC Curve, Anemia etiology, Anemia blood, Trismus etiology, Hemoglobins analysis, Nasopharyngeal Neoplasms radiotherapy, Nasopharyngeal Neoplasms blood, Chemoradiotherapy adverse effects
- Abstract
Purpose: To investigate the predictive significance of hemoglobin (Hb) values in the incidence of radiation-induced trismus (RIT) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients who received concurrent chemoradiotherapy (C-CRT)., Methods: Data of LA-NPC patients were examined before and after C-CRT and to confirm the presence of RIT, maximum mouth openings (MMO) were measured; RIT is defined as an MMO of ≤35 mm. All Hb values were derived from complete blood count tests obtained on the first day of C-CRT. The receiver operating characteristic (ROC) curve analysis was used to scrutinize a possible connection between pre-treatment Hb values and RIT status., Results: Two hundred and twenty three patients were included in the study and RIT was diagnosed in 46 (20.6%) patients. The Hb cutoff in ROC curve analysis that separated the patients into two groups was 12.05 g/dL [Area under the curve (AUC): 82.7%; sensitivity: 72.9%; and specificity: 71.3%]. RIT was significantly more prevalent in the Hb ≤ 12 g/dL group than in its counterpart (41.9% vs. 7.3%; p < 0.001). In multivariate analysis, Hb ≤ 12, anemia, pre-C-CRT MMO < 41.4 mm, and masticatory apparatus doseV58 Gy < 32% groups were found to be independently associated with significantly increased rates of RIT., Conclusion: Low pre-C-CRT Hb and anemia status are novel biological markers that independently predict higher RIT rates in LA-NPC undergoing C-CRT., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
5. Comment on 'accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID-19 pandemic: A tertiary care experience'.
- Author
-
Somay E, Topkan E, Selek U, and Pehlivan B
- Subjects
- Humans, Tertiary Healthcare, Pandemics, COVID-19 epidemiology, Head and Neck Neoplasms therapy, Chemoradiotherapy methods, Radiation Dose Hypofractionation, SARS-CoV-2
- Published
- 2024
- Full Text
- View/download PDF
6. Comment on Prospective Study to Compare Efficacy of Conventional Chemoradiotherapy with Hypofractionated Chemoradiotherapy in Locally Advanced Carcinoma of Oropharynx.
- Author
-
Topkan E, Somay E, and Selek U
- Subjects
- Humans, Prospective Studies, Oropharynx, Chemoradiotherapy, Carcinoma
- Published
- 2024
- Full Text
- View/download PDF
7. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
- Author
-
Topkan E, Yucel Ekici N, Ozdemir Y, Besen AA, Mertsoylu H, Sezer A, and Selek U
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Cisplatin therapeutic use, Female, Humans, Karnofsky Performance Status, Male, Middle Aged, Multivariate Analysis, Nasopharyngeal Carcinoma physiopathology, Nasopharyngeal Carcinoma therapy, Nasopharyngeal Neoplasms physiopathology, Nasopharyngeal Neoplasms therapy, Neoplasm Staging, Predictive Value of Tests, Prognosis, ROC Curve, Retrospective Studies, Treatment Outcome, Chemoradiotherapy mortality, Nasopharyngeal Carcinoma mortality, Nasopharyngeal Neoplasms mortality, Nutrition Assessment, Nutritional Status
- Abstract
Background: To retrospectively assess the impact of prognostic nutritional index (PNI) on survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with concurrent chemoradiotherapy (CCRT)., Methods: This study incorporated 154 patients with LA-NPC who received exclusive cisplatinum-based CCRT. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of pretreatment PNI cutoffs influencing survival results. The primary end point was the interaction between the overall survival (OS) and PNI values, while cancer-specific survival (CSS) locoregional progression-free survival (LR-PFS), distant metastasis-free survival (DMFS), and PFS were the secondary end points., Results: A rounded PNI cutoff value of 51 was identified in ROC curve analyses to exhibit significant link with CSS, OS, DMFS, and PFS outcomes, but not LR-PFS. Patients grouping per PNI value (≥51 [N = 95] vs <51 [N = 49]) revealed that PNI < 51 group had significantly shorter median CSS ( P < .001), OS ( P < .001), DMFS ( P < .001), and PFS ( P < .001) times than the PNI ≥ 51 group, and the multivariate results confirmed the PNI < 51 as an independent predictor of poor outcomes for each end point ( P < .05 for each). The unfavorable impact of the low PNI was also continued at 10-year time point with survival rates of 77.9% versus 42.4%, 73.6% versus 33.9%, 57.9% versus 27.1%, and 52.6% versus 23.7% for CSS, OS, DMFS, and PFS, respectively. Additionally, we found that PNI < 51 was significantly associated with higher rates of weight loss >5% over past 6 months (49.2% versus 11.6%; P = .002) compared to PNI < 51 group., Conclusion: Low pre-CCRT PNI levels were independently associated with significantly reduced CSS, OS, DMFS, and PFS outcomes in patients with LA-NPC treated with definitive CCRT.
- Published
- 2021
- Full Text
- View/download PDF
8. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
- Author
-
Topkan E, Ozdemir Y, Kucuk A, Besen AA, Mertsoylu H, Sezer A, and Selek U
- Subjects
- Adult, Aged, Carcinoma, Non-Small-Cell Lung pathology, Female, Humans, Lymph Nodes drug effects, Lymph Nodes pathology, Lymph Nodes radiation effects, Male, Middle Aged, Neoplasm Staging, Progression-Free Survival, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Chemoradiotherapy
- Abstract
Background: To investigate the detrimental effects of prolonged overall radiotherapy duration (ORTD) on survival outcomes of stage IIIB/C NSCLC patients treated with concurrent chemoradiotherapy (C-CRT)., Methods: The study cohort consisted of 956 patients who underwent C-CRT for stage IIIB/C NSCLC. Primary endpoint was the association between the ORTD and overall survival (OS) with locoregional progression-free survival (LRPFS) and PFS comprising the secondary endpoints. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of the cut-off that interacts with survival outcomes. Multivariate Cox model was utilized to identify the independent associates of survival outcomes., Results: The ROC curve analysis exhibited significance at 49 days of ORTD cut-off that dichotomized patients into ORTD<50 versus ORTD≥50 days groups for OS [area under the curve (AUC): 82.8%; sensitivity: 81.1%; specificity: 74.8%], LRPFS (AUC: 91.9%; sensitivity: 90.6%; specificity: 76.3%), and PFS (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%), respectively. Accordingly, ORTD≥50 days group had significantly shorter median OS (P<0.001), LRPFS (P<0.001), and PFS (P<0.001); and 10-year actuarial locoregional control (P<0.001) and distant metastases-free (P<0.011) rates than the ORTD<50 days group. The ORTD retained its significant association with survival outcomes at multivariate analyses independent of the other favorable covariates (p<0.001, for OS, LRPFS, and PFS): Stage IIIB disease (versus IIIC), lymph node bulk <2 cm (versus ≥2 cm), and 2-3 chemotherapy cycles (versus 1). The higher sensitivity for LRPFS (90.6%) than PFS (72.4%) on ROC curve analysis suggested the prolonged ORTD-induced decrements in locoregional control rates as the major cause of the poor survival outcomes., Conclusions: Longer ORTD beyond ≥50 days was associated with significantly poorer OS, LRPFS and PFS outcomes, where reduced locoregional control rates appeared to be the main causative., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
9. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
- Author
-
Topkan E, Bolukbasi Y, Ozdemir Y, Besen AA, Mertsoylu H, and Selek U
- Subjects
- Adenocarcinoma of Lung metabolism, Adenocarcinoma of Lung pathology, Aged, C-Reactive Protein metabolism, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Female, Humans, Lung Neoplasms metabolism, Lung Neoplasms pathology, Male, Multivariate Analysis, Neoplasm Staging, Prognosis, Progression-Free Survival, Serum Albumin metabolism, Survival Rate, Adenocarcinoma of Lung therapy, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Lung Neoplasms therapy
- Abstract
Objectives: To investigate the prognostic significance of pre-treatment Glasgow prognostic score (GPS) in stage IIIB non-small-cell lung cancer (NSCLC) older patients treated with radical concurrent chemoradiotherapy (C-CRT)., Materials and Methods: We included 83 stage IIIB NSCLC older patients (age > 70 years) treated with C-CRT consisting of 60-66 Gy (2 Gy/fx) thoracic radiotherapy and at least 1 cycle of platinum-based chemotherapy. Patients were grouped into three: GPS-0: c-reactive protein (CRP) ≤ 10 mg/L and albumin >35 g/L, GPS-1: CRP ≤ 10 mg/L and albumin ≤35 g/L or CRP > 10 mg/L and albumin >35 g/L, GPS-2: CRP > 10 mg/L and albumin ≤35 g/L according to the definition. The relationship between GPS groups and overall survival (OS) was the primary objective, while locoregional- (LRPFS) and progression-free survival (PFS) were secondary objectives., Results: For the whole cohort, the median OS, LRPFS, and OS were 19.7 (95% confidence interval [CI]: 16.8-22.6), 13.2 (95% CI: 8.7-17.7), and 8.3 months (95% CI: 6.6-10.0), respectively. Comparisons between the GPS-0, GPS-1, and GPS -2 groups revealed that the lower GPS was associated with significantly superior median OS (25.8 versus 16.3 versus 9.4 months; p < .001) which retained its independent significance in multivariate analysis (p < .001), as well. Similarly, the respective median LRPFS (20.0 versus 10.4 versus 6.3 months; p < .001), and PFS (11.3 versus 7.3 versus 4.1 months; p < .001) durations were also significantly longer in the earlier GPS groups., Discussion: The present results suggested that the GPS was useful in three layered stratification of older stage IIIB NSCLC patients undergoing C-CRT in terms of OS, LRPS, and PFS times., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy.
- Author
-
Topkan E, Ekici NY, Ozdemir Y, Besen AA, Yildirim BA, Mertsoylu H, Sezen D, and Selek U
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell therapy, Chemoradiotherapy adverse effects, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nasopharyngeal Neoplasms blood, Nasopharyngeal Neoplasms pathology, Nasopharyngeal Neoplasms therapy, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Anemia etiology, Carcinoma, Squamous Cell mortality, Chemoradiotherapy mortality, Hemoglobins analysis, Nasopharyngeal Neoplasms mortality
- Abstract
Background: To retrospectively investigate the influence of pretreatment anemia and hemoglobin levels on the survival of nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy (C-CRT)., Methods: A total of 149 nasopharyngeal carcinoma patients who received C-CRT were included. All patients had received 70 Gy to the primary tumor plus the involved lymph nodes, and 59.4 Gy and 54 Gy to the intermediate- and low-risk neck regions concurrent with 1-3 cycles of cisplatin. Patients were dichotomized into non-anemic and anemic (hemoglobin <12 g/dL (women) or <13 g/dL (men)) groups according to their pre-treatment hemoglobin measures. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of a pre-treatment hemoglobin cut-off that impacts outcomes. Potential interactions between baseline anemia status and hemoglobin measures and overall survival, locoregional progression-free survival (LRPFS), and progression-free survival were assessed., Results: Anemia was evident in 36 patients (24.1%), which was related to significantly shorter overall survival ( P =0.007), LRPFS ( P <0.021), and progression-free survival ( P =0.003) times; all three endpoints retained significance in multivariate analyses ( P <0.05, for each). A baseline hemoglobin value of 11.0 g/dL exhibited significant association with outcomes in ROC curve analysis: hemoglobin <11.0 g/dL (N=26) was linked with shorter median overall survival ( P <0.001), LRPFS ( P =0.004), and progression-free survival ( P <0.001) times, which also retained significance for all three endpoints in multivariate analyses and suggested a stronger prognostic worth for the hemoglobin <11.0 g/dL cut-off value than the anemia status., Conclusion: Pre-C-CRT hemoglobin <11.0 g/dL has a stronger prognostic worth than the anemia status with regard to LRPFS, progression-free survival, and overall survival for nasopharyngeal carcinoma patients.
- Published
- 2019
- Full Text
- View/download PDF
11. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
- Author
-
Guler OC, Yıldırım BA, Önal C, and Topkan E
- Subjects
- Adult, Aged, Brain Neoplasms pathology, Brain Neoplasms therapy, Dose Fractionation, Radiation, Female, Follow-Up Studies, Glioblastoma pathology, Glioblastoma therapy, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Antineoplastic Agents, Alkylating therapeutic use, Brain Neoplasms mortality, Chemoradiotherapy mortality, Glioblastoma mortality, Temozolomide therapeutic use
- Abstract
Background: To compare the efficacies of standard dose-(SDRT) and escalated dose radiotherapy (EDRT) in newly diagnosed glioblastoma (GBM) with concurrent and adjuvant temozolomide (TMZ)., Materials and Methods: Outcomes of 126 newly diagnosed GBM patients who received SDRT (60 Gy, 30 fractions) or EDRT (70 Gy, 30 fractions) with concurrent plus adjuvant TMZ were retrospectively analyzed. Both groups received concurrent TMZ (75 mg/m
2 ) during the course of RT and at least one course of adjuvant TMZ (150-200 mg/m2 ), thereafter. Overall survival (OS) and local progression free survival (LPFS) constituted the primary and secondary endpoints, respectively., Results: At median 14.2 months follow-up, 26 (20.6%) patients were alive. Median LPFS and OS were 9.2 [95% confidence interval (CI); 8.4-10.0] and 15.4 months (95% CI; 12.1-18.8), respectively, for the entire cohort. Although the median OS was numerically superior in the EDRT this difference could not reach statistical significance (22.0 vs. 14.9 months; P = 0.45), Likewise, LPFS was also (9.9 vs. 8.9 months; P = 0.89) not different between the two treatment groups. In multivariate analysis, better recursive partitioning analysis class (3-4 vs. 5; P = 0.044) and extensive surgery (gross total resection vs. subtotal resection/biopsy only; P= 0.021) were identified to associate significantly with superior OS times, irrespective of the RT protocol., Conclusions: Although the current median OS of 22 months of the EDRT group is promising, no statistically significant survival advantage for EDRT was observed even in the presence of TMZ. Randomized studies with larger population sizes and available genetic markers are warranted to conclude more reliably on the fate of EDRT plus TMZ., Competing Interests: There are no conflicts of interest.- Published
- 2019
- Full Text
- View/download PDF
12. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
- Author
-
Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, Besen AA, Findikcioglu A, and Ozyilkan O
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell epidemiology, Carcinoma, Squamous Cell mortality, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Incidence, Lung Neoplasms epidemiology, Lung Neoplasms mortality, Magnetic Resonance Imaging, Male, Middle Aged, Multivariate Analysis, Prognosis, Progression-Free Survival, Proportional Hazards Models, Radiotherapy Dosage, Retrospective Studies, Time Factors, Treatment Outcome, Carcinoma, Squamous Cell therapy, Chemoradiotherapy methods, Lung Neoplasms therapy, Necrosis
- Abstract
Purpose: To investigate the incidence and influence of tumor cavitation (TC) on survival outcomes of locally advanced squamous cell lung cancer (LA-SqCLC) patients treated with concurrent chemoradiation therapy (C-CRT)., Methods and Materials: Records of 789 stages IIIA/B squamous cell lung cancer (SqCLC) patients treated with C-CRT who received 1 to 3 cycles of platinum-based doublet chemotherapy during 60 to 66 Gy radiation therapy (RT) were analyzed retrospectively. Primary endpoint was the association between overall survival (OS) and pretreatment TC status. Secondary endpoints included locoregional progression-free survival (LRPFS), progression-free survival (PFS), and incidence of TC and correlated factors., Results: Pretreatment TC occurred in 95 patients (12%), being significantly more common in those patients with ever-smoking history (12.6% vs 3.9%; P < .001), weight loss >5% (20.9% vs 7.1%; P < .001), and hemoptysis (27.1% vs 6.4%; P < .001). Rates of acute and late toxicities were similar in patients who presented with and without TC (P > .05 for each). For the whole cohort, at a median follow-up of 22.9 months (range: 2.4-71.1), the respective median OS, LRPFS, and PFS estimates were 23.7, 14.7, and 10.7 months. In multivariate analysis, stage IIIB disease (P < .001; hazard ratio [HR]: 1.33; 95% CI: 1.21-1.45), weight loss >5% (P < .001; HR: 2.10; 95% CI: 1.85-2.35), anemia (P < .001; HR: 1.82; 95% CI: 1.67-1.97), and presence of TC (P < .001; HR: 1.54; 95% CI: 1.37-1.71) appeared to be independently associated with poorer OS durations, likewise the LRPFS (P < .001 for each of these covariates), and PFS (P < .001 for each of these covariates), respectively., Conclusions: Present results showed that the TC occurred in 12% of LA-SqCLC patients, which was strongly associated with poorer PFS, LRPFS, and OS outcomes after definitive C-CRT., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
13. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
- Author
-
Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Mertsoylu H, and Hahn SM
- Subjects
- Adult, Aged, Anemia etiology, Anemia mortality, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung therapy, Drug-Related Side Effects and Adverse Reactions mortality, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms therapy, Male, Middle Aged, Neoplasm Staging, Prognosis, Risk Factors, Sex Factors, Survival Analysis, Anemia diagnosis, Carcinoma, Non-Small-Cell Lung diagnosis, Chemoradiotherapy adverse effects, Drug-Related Side Effects and Adverse Reactions diagnosis, Hemoglobins metabolism, Lung Neoplasms diagnosis
- Abstract
Purpose: We investigated the influence of change in hemoglobin (Hgb) levels during concurrent chemoradiotherapy (C-CRT) on outcomes of non-anemic patients with stage IIIA/B non-small cell lung cancer (NSCLC)., Methods: We identified 722 patients with stage IIIA/B NSCLC without anemia at baseline [hemoglobin (Hgb) <12 g/dL for women or <13 g/dL for men], either nonsmokers or ex-smokers, who received C-CRT between 2007 and 2012. All patients had received 1-3 cycles of platinum-based doublet chemotherapy during radiotherapy to 60-66 Gy and had documented Hgb measurements before treatment and at weekly intervals for 6 weeks during the C-CRT. Potential associations were assessed between baseline, nadir, extent of change in Hgb level, and anemia and overall survival (OS), locoregional progression-free survival (LRPFS), and PFS., Results: The median baseline Hgb level was 13.9 g/dL (range 12.0-16.8) and declined to a median 12.4 g/dL (range 7.9-16.1) during treatment. Anemia appeared in 237 patients (32.8%) and was more common among women (44.8% vs. 26.5%, P < 0.001). Neither baseline Hgb level nor change during treatment nor anemia emergence influenced any survival endpoint. Receiver operating curve analysis revealed an Hgb nadir of 11.1 g/dL to be associated with outcomes, in that a nadir Hgb <11.1 g/dL (in 156 patients) was linked with shorter median OS time (P < 0.001), LRPFS time (P < 0.001), and PFS time (P < 0.001); retained significance for all three endpoints in multivariate analyses; and was more strongly associated with OS in squamous cell carcinoma (P < 0.001) than in adenocarcinoma (P = 0.009)., Conclusion: Nadir Hgb <11.1 g/dL levels during C-CRT were associated with significantly poorer survival times in initially non-anemic patients presenting with locally advanced NSCLC., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
14. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
- Author
-
Parlak C, Mertsoylu H, Güler OC, Onal C, and Topkan E
- Subjects
- Adult, Aged, Analysis of Variance, Brain Neoplasms mortality, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Chemoradiotherapy adverse effects, Cisplatin administration & dosage, Combined Modality Therapy adverse effects, Combined Modality Therapy methods, Cranial Irradiation adverse effects, Disease-Free Survival, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging methods, Radiosurgery adverse effects, Retrospective Studies, Brain Neoplasms secondary, Brain Neoplasms therapy, Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy methods, Cranial Irradiation methods, Lung Neoplasms therapy, Radiosurgery methods
- Abstract
Purpose/objectives: The aim of this study was to evaluate the impact of definitive thoracic chemoradiation therapy following surgery or stereotactic radiosurgery (SRS) and whole-brain radiation therapy (WBRT) on the outcomes of patients with non-small cell lung cancer (NSCLC) with synchronous solitary brain metastasis (SSBM)., Methods and Materials: A total of 63 NSCLC patients with SSBM were retrospectively evaluated. Patients were staged using positron emission tomography-computed tomography in addition to conventional staging tools. Thoracic radiation therapy (TRT) with a total dose of 66 Gy in 2 Gy fractions was delivered along with 2 cycles of cisplatin-based chemotherapy following either surgery plus 30 Gy of WBRT (n=33) or SRS plus 30 Gy of WBRT (n=30) for BM., Results: Overall, the treatment was well tolerated. All patients received planned TRT, and 57 patients (90.5%) were also able to receive 2 cycles of chemotherapy. At a median follow-up of 25.3 months (7.1-52.1 months), the median months of overall, locoregional progression-free, neurological progression-free, and progression-free survival were 28.6, 17.7, 26.4, and 14.6, respectively. Both univariate and multivariate analyses revealed that patients with a T1-T2 thoracic disease burden (P=.001), a nodal stage of N0-N1 (P=.003), and no weight loss (P=.008) exhibited superior survival., Conclusions: In the present series, surgical and radiosurgical treatments directed toward SSBM in NSCLC patients were equally effective. The similarities between the present survival outcomes and those reported in other studies for locally advanced NSCLC patients indicate the potentially curative role of definitive chemoradiation therapy for highly selected patients with SSBM., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
15. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
- Author
-
Topkan E, Parlak C, and Selek U
- Subjects
- Adult, Aged, Analysis of Variance, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Body Mass Index, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung secondary, Cisplatin administration & dosage, Disease-Free Survival, Docetaxel, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Radiotherapy Dosage, Retrospective Studies, Survival Analysis, Taxoids administration & dosage, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Weight Gain physiology, Weight Loss physiology, Body Weight physiology, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy adverse effects, Lung Neoplasms mortality, Lung Neoplasms therapy
- Abstract
Purpose: We retrospectively investigated the impact of weight change (WC) during concurrent chemoradiation therapy (C-CRT) on clinical outcomes of stage 3B non-small cell lung cancer (NSCLC) patients., Methods and Materials: A total of 425 patients treated with C-CRT were included. All patients received 60 to 66 Gy of thoracic radiation therapy concurrently with 1 to 3 cycles of platinum-based chemotherapy. Pre- and posttreatment weight measurements on first and last days of C-CRT were used for WC. Patients were divided into 2 groups: group 1=weight loss (WL); group 2=weight preservation/gain (WP) for comparative analyses., Results: Following C-CRT, 252 patients (59.3%) experienced WL, while 89 patients (20.9%) and 84 patients (19.8%) showed WP or WG. At median 24.2 months of follow-up, 142 patients (33.4%) were alive (84 WP [48.6%] and 58 WL [23.0%]), and 58 (13.6%) of them were free of disease progression (41 [23.7%] for WP and 17 [6.7%] for WL). Median overall survival (OS), locoregional progression-free survival (LRPFS), progression-free survival (PFS), and distant metastases-free survival (DMFS) for the entire population were 22.8, 14.4, 10.6, and 11.7 months, respectively. Intergroup comparisons between WP and WL cohorts revealed significantly superior OS, LRPFS, PFS, and DMFS in WP patients (P<.05 for each). On multivariate analyses, only WL and advanced T stage were associated with poor prognosis (P<.05)., Conclusions: Present results in 425 stage 3B NSCLC patients demonstrated that WL during C-CRT is strongly associated with inferior survival outcomes compared to WP. This emerging finding might be useful by forming an encouraging basis for future investigations in facilitating a way to improve the outcomes of these patients experiencing WL during C-CRT., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
16. FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy.
- Author
-
Topkan E, Parlak C, and Yapar AF
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms mortality, Pancreatic Neoplasms therapy, Pancreatic Neoplasms, Chemoradiotherapy adverse effects, Fluorodeoxyglucose F18, Pancreatic Neoplasms pathology, Positron-Emission Tomography methods, Radiopharmaceuticals, Tomography, X-Ray Computed methods
- Abstract
The impact of [(18)F]fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) restaging on management decisions and outcomes in patients with locally advanced pancreatic carcinoma (LAPC) scheduled for concurrent chemoradiotherapy (CRT) is examined. Seventy-one consecutive patients with conventionally staged LAPC were restaged with PET/CT before CRT, and were categorized into non-metastatic (M0) and metastatic (M1) groups. M0 patients received 50.4 Gy CRT with 5-fluorouracil followed by maintenance gemcitabine, whereas M1 patients received chemotherapy immediately or after palliative radiotherapy. In 19 patients (26.8%), PET/CT restaging showed distant metastases not detected by conventional staging. PET/CT restaging of M0 patients showed additional regional lymph nodes in 3 patients and tumors larger than CT-defined borders in 4. PET/CT therefore altered or revised initial management decisions in 26 (36.6%) patients. At median follow-up times of 11.3, 14.5, and 6.2 months for the entire cohort and the M0 and M1 cohorts, respectively, median overall survival was 16.1, 11.4, and 6.2 months, respectively; median locoregional progression-free survival was 9.9, 7.8, and 3.4 months, respectively; and median progression-free survival was 7.4, 5.1, and 2.5 months, respectively (P < 0.05 each). These findings suggest that PET/CT-based restaging may help select patients suitable for CRT, sparing those with metastases from futile radical protocols, and increasing the accuracy of estimated survival.
- Published
- 2013
- Full Text
- View/download PDF
17. In regard to Bjerregaard et al. Re: Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
- Author
-
Parlak C and Topkan E
- Subjects
- Female, Humans, Male, Chemoradiotherapy methods, Pancreatic Neoplasms therapy
- Published
- 2013
- Full Text
- View/download PDF
18. Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy.
- Author
-
Topkan E, Parlak C, and Yapar F
- Subjects
- Adult, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease Progression, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Pancreatic Neoplasms mortality, Positron-Emission Tomography, Tomography, X-Ray Computed, Treatment Outcome, Gemcitabine, Adenocarcinoma drug therapy, Adenocarcinoma radiotherapy, Chemoradiotherapy adverse effects, Lymphatic Irradiation methods, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms radiotherapy
- Abstract
Background: We evaluated influence of limited-field radiotherapy with no elective nodal irradiation (ENI) on outcomes and toxicity profile in patients with locally advanced pancreatic adenocarcinoma (LAPAC), treated with definitive concurrent chemoradiotherapy (C-CRT)., Methods: Thirty-five patients with histological proof of LAPAC underwent 50.4Gy of C-CRT with 5-FU followed by maintenance gemcitabine. Target volume included primary tumor and lymph nodes that appeared to be involved on either contrast-enhanced computerized tomography or 18F-fluoro-deoxyglucose positron emission tomography., Results: No grade 4/5 acute/late toxicity was reported at median 15.7 months. Acute hematologic plus non-hematologic grade 3 toxicity was noted in 10 (28.6%) patients. At long-term, 2 patients (5.7%) experienced grade 3 gastric outlet obstructions at 8.7 and 10.9 months, respectively. No isolated regional relapses were noted. Median overall-survival (OS), progression-free survival (PFS), and locoregional-PFS (LRPFS) were 15.2, 9.1 and 7.3 months, respectively. Corresponding 1- and 2-year survival estimates were 60.0% and 20.0% for OS, 41.9% and 17.4% for LRPFS, and 34.0% and 12.7% for PFS, respectively., Conclusions: Compared to ENI literature, first report of a limited-field C-CRT study carried out in Turkey showed that omission of ENI was relatively well tolerated without compromising survival and locoregional control rates in patients with LAPAC., (Copyright © 2012 IAP and EPC. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
19. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
- Author
-
Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, and Pehlivan B
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms mortality, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung therapy, Cisplatin administration & dosage, Docetaxel, Female, Humans, Induction Chemotherapy methods, Lung Neoplasms mortality, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local mortality, Retrospective Studies, Taxoids administration & dosage, Time Factors, Turkey, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Brain Neoplasms prevention & control, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung prevention & control, Carcinoma, Non-Small-Cell Lung secondary, Chemoradiotherapy methods, Cranial Irradiation methods, Lung Neoplasms therapy
- Abstract
Purpose: To retrospectively assess the influence of prophylactic cranial irradiation (PCI) timing on brain relapse rates in patients treated with two different chemoradiotherapy (CRT) regimens for Stage IIIB non-small-cell lung cancer (NSCLC)., Methods and Materials: A cohort of 134 patients, with Stage IIIB NSCLC in recursive partitioning analysis Group 1, was treated with PCI (30 Gy at 2 Gy/fr) following one of two CRT regimens. Regimen 1 (n = 58) consisted of three cycles of induction chemotherapy (ICT) followed by concurrent CRT (C-CRT). Regimen 2 (n = 76) consisted of immediate C-CRT during thoracic radiotherapy., Results: At a median follow-up of 27.6 months (range, 7.2-40.4), 65 patients were alive. Median, progression-free, and brain metastasis-free survival (BMFS) times for the whole study cohort were 23.4, 15.4, and 23.0 months, respectively. Median survival time and the 3-year survival rate for regimens 1 and 2 were 19.3 vs. 26.1 months (p = 0.001) and 14.4% vs. 34.4% (p < .001), respectively. Median time from the initiation of primary treatment to PCI was 123.2 (range, 97-161) and 63.4 (range, 55-74) days for regimens 1 and 2, respectively (p < 0.001). Overall, 11 (8.2%) patients developed brain metastasis (BM) during the follow-up period: 8 (13.8%) in regimen 1 and 3 (3.9%) in regimen 2 (p = 0.03). Only 3 (2.2%) patients developed BM at the site of first failure, and for 2 of them, it was also the sole site of recurrence. Median BMFS for regimens 1 and 2 were 17.4 (13.5-21.3) vs. 26.0 (22.9-29.1 months), respectively (p < 0.001)., Conclusion: These results suggest that in Stage IIIB NSCLC patients treated with PCI, lower BM incidence and longer survival rates result from immediate C-CRT rather than ITC-first regimens. This indicates the benefit of earlier PCI use without delay because of induction protocols., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
20. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
- Author
-
Parlak C, Topkan E, Onal C, Reyhan M, and Selek U
- Subjects
- Adult, Aged, Area Under Curve, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms therapy, Prognosis, ROC Curve, Radiopharmaceuticals, Chemoradiotherapy, Multimodal Imaging methods, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Positron-Emission Tomography, Radiotherapy Planning, Computer-Assisted methods, Tomography, X-Ray Computed, Tumor Burden drug effects, Tumor Burden radiation effects
- Abstract
Background: We aimed to assess whether gross tumor volume (GTV) determined by fusion of contrast-enhanced computerized tomography (CT) and 18F-fluoro-deoxy-D-glucose positron emission tomography-CT (FDG-PET-CT) based radiotherapy planning could predict outcomes, namely overall survival (OS), local-regional progression-free survival (LRPFS), and progression-free survival (PFS) in cases with locally advanced pancreas cancer (LAPC) treated with definitive concurrent chemoradiotherapy., Methods: A total of 30 patients with histological proof of LAPC underwent 50.4 Gy (1.8 Gy/28 fractions) of radiotherapy concurrent with continuously infused 5-FU followed by 4 to 6 courses of maintenance gemcitabine. Target volume delineations were performed on FDG-PET-CT-based RTP. Patients were stratified into 2 groups: GTV lesser (GTVL) versus greater (GTVG) than cut off value determined by receiver operating characteristic (ROC) analysis, and compared in terms of OS, LRPFS and PFS., Results: Median GTV delineated according to the FDG-PET-CT data was 100.0 cm3. Cut off GTV value determined from ROC curves was 91.1 cm3. At a median follow up of 11.2 months, median OS, LRPFS and PFS for the entire population were 10.3, 7.8 and 5.7 months, respectively. Median OS, LRPFS and PFS for GTVL and GTVG cohorts were 16.3 vs. 9.5 (p = 0.005), 11.0 vs. 6.0 (p = 0.013), and 9.0 vs. 4.8 months (p = 0.008), respectively., Conclusions: The superior OS, LRPFS and PFS observed in GTVL patients over GTVG ones suggests a potential for FDG-PET-CT-defined GTV size in predicting outcomes of LAPC patients treated with definitive C-CRT, which needs to be validated by further studies with larger cohorts.
- Published
- 2012
- Full Text
- View/download PDF
21. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
- Author
-
Topkan E, Parlak C, Kotek A, Yapar AF, and Pehlivan B
- Subjects
- Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Carcinoma therapy, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Neoplasm Recurrence, Local, Pancreatic Neoplasms therapy, Predictive Value of Tests, Radiopharmaceuticals, Gemcitabine, Carcinoma mortality, Carcinoma radiotherapy, Chemoradiotherapy, Multimodal Imaging, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms mortality, Positron-Emission Tomography, Tomography, X-Ray Computed
- Abstract
Background: We aimed to study the predictive value of combined 18F-fluoro-deoxy-D-glucose positron emission tomography and computerized tomography (FDG-PET-CT), on outcomes in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (C-CRT)., Methods: Thirty-two unresectable LAPC patients received 50.4 Gy (1.8 Gy/fr) of RT and concurrent 5-FU followed by 4 to 6 cycles of gemcitabine consolidation. Response was evaluated by FDG-PET-CT at post-C-CRT 12-week. Patients were stratified into two groups according to the median difference between pre- and post-treatment maximum standard uptake values (SUVmax) as an indicator of response for comparative analysis., Results: At a median follow-up of 16.1 months, 16 (50.0%) patients experienced local/regional failures, 6 of which were detected on the first follow-up FDG-PET-CT. There were no marginal or isolated regional failures. Median pre- and post-treatment SUVmax and median difference were 14.5, 3.9, and -63.7%, respectively. Median overall survival (OS), progression-free survival (PFS), and local-regional progression-free survival (LRPFS) were 14.5, 7.3, and 10.3 months, respectively. Median OS, PFS, and LRPFS for those with greater (N = 16) versus lesser (N = 16) SUVmax change were 17.0 versus 9.8 (p = 0.001), 8.4 versus 3.8 (p = 0.005), and 12.3 versus 6.9 months (p = 0.02), respectively. On multivariate analysis, SUVmax difference was predictive of OS, PFS, and LRPFS, independent of existing covariates., Conclusions: Significantly higher OS, PFS, and LRPFS in patients with greater SUVmax difference suggest that FDG-PET-CT-based metabolic response assessment is an independent predictor of clinical outcomes in LAPC patients treated with definitive C-CRT.
- Published
- 2011
- Full Text
- View/download PDF
22. Predicting Teeth Extraction after Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer Patients Using the Novel GLUCAR Index.
- Author
-
Somay, Efsun, Topkan, Erkan, Yilmaz, Busra, Besen, Ali Ayberk, Mertsoylu, Hüseyin, and Selek, Ugur
- Subjects
- *
DENTAL extraction , *NASOPHARYNX cancer , *CANCER patients , *CHEMORADIOTHERAPY , *MULTIVARIATE analysis - Abstract
To evaluate the value of the newly created GLUCAR index in predicting tooth extraction rates after concurrent chemoradiotherapy (C-CRT) in locally advanced nasopharyngeal carcinomas (LA-NPCs). Methods: A total of 187 LA-NPC patients who received C-CRT were retrospectively analyzed. The GLUCAR index was defined as ′GLUCAR = (Fasting Glucose × CRP/Albumin Ratio) by utilizing measures of glucose, C-reactive protein (CRP), and albumin obtained on the first day of C-CRT. Results: The optimal GLUCAR cutoff was 31.8 (area under the curve: 78.1%; sensitivity: 70.5%; specificity: 70.7%, Youden: 0.412), dividing the study cohort into two groups: GLUCAR ˂ 1.8 (N = 78) and GLUCAR ≥ 31.8 (N = 109) groups. A comparison between the two groups found that the tooth extraction rate was significantly higher in the group with a GLUCAR ≥ 31.8 (84.4% vs. 47.4% for GLUCAR ˂ 31.8; odds ratio (OR):1.82; p < 0.001). In the univariate analysis, the mean mandibular dose ≥ 38.5 Gy group (76.5% vs. 54.9% for <38.5 Gy; OR: 1.45; p = 0.008), mandibular V55.2 Gy group ≥ 40.5% (80.3 vs. 63.5 for <40.5%, p = 0.004, OR; 1.30), and being diabetic (71.8% vs. 57.9% for nondiabetics; OR: 1.23; p = 0.007) appeared as the additional factors significantly associated with higher tooth extraction rates. All four characteristics remained independent predictors of higher tooth extraction rates after C-CRT in the multivariate analysis (p < 0.05 for each). Conclusions: The GLUCAR index, first introduced here, may serve as a robust new biomarker for predicting post-C-CRT tooth extraction rates and stratifying patients according to their tooth loss risk after treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
- Author
-
Pehlivan, Umur Anil, Somay, Efsun, Yilmaz, Busra, Besen, Ali Ayberk, Mertsoylu, Huseyin, Selek, Ugur, and Topkan, Erkan
- Subjects
NASOPHARYNX cancer ,CHEMORADIOTHERAPY ,RECEIVER operating characteristic curves ,MAGNETIC resonance imaging ,SURVIVAL rate ,NASOPHARYNX ,MASSETER muscle - Abstract
Background and purpose: Muscle loss is a significant indicator of cancer cachexia and is associated with a poor prognosis in cancer patients. Given the absence of comparable studies, the current retrospective study sought to examine the correlation between the total masseter muscle volume (TMMV) before treatment and the survival outcomes in locally advanced nasopharyngeal cancer (LA-NPC) patients who received definitive concurrent chemoradiotherapy (CCRT). Methods: A three-dimensional segmentation model was used to determine the TMMV for each patient by analyzing pre-CCRT magnetic resonance imaging. The optimal TMMV cutoff values were searched using receiver operating characteristic (ROC) curve analyses. The primary and secondary endpoints were the relationship between the pre-CCRT TMMV measures and overall survival (OS) and progression-free survival (PFS), respectively. Results: Ninety-seven patients were included in this study. ROC curve analyses revealed 38.0 cc as the optimal TMMV cutoff: ≤38.00 cc (n = 42) and >38.0 cc (n = 55). Comparisons between the two groups showed that the TMMV>38.0 cc group had significantly longer PFS [Not reached (NR) vs. 28; p < 0.01] and OS (NR vs. 71; p < 0.01) times, respectively. The results of the multivariate analysis demonstrated that the T-stage, N-stage, number of concurrent chemotherapy cycles, and TMMV were independent associates of PFS (p < 0.05 for each) and OS (p < 0.05 for each) outcomes, respectively. Conclusion: The findings of the current retrospective research suggest that pretreatment TMMV is a promising indicator for predicting survival outcomes in LA-NPC patients receiving definitive CCRT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Hemoglobin‐to‐platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy.
- Author
-
Somay, Efsun, Yilmaz, Busra, Topkan, Erkan, Kucuk, Ahmet, Haksoyler, Veysel, Pehlivan, Berrin, Selek, Ugur, and Araz, Kenan
- Subjects
NASOPHARYNX cancer ,HEMOGLOBINS ,BLOOD platelets ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,TRISMUS ,CHEMORADIOTHERAPY ,RISK assessment ,CANCER patients ,RECEIVER operating characteristic curves - Abstract
Objective: The significance of pre‐hemoglobin‐to‐platelet ratio (HPR) in predicting the occurrence of radiation‐induced trismus (RIT) in locally advanced nasopharyngeal carcinoma patients (LA‐NPC) who received concurrent chemoradiotherapy (C‐CRT). Methods: The records of LA‐NPC patients with oral examination before and after C‐CRT were analyzed. Maximum mouth openings (MMO) were measured before and after C‐CRT to confirm RIT status, with an MMO of ≤35 mm defined as RIT. HPR values were calculated on the first day of C‐CRT. The relationship between the HPR values and RIT status was discovered using the receiver operating characteristic curve analysis. Results: A total of 43 patients RIT cases among 198 individuals were diagnosed. The optimal HPR cutoff that stratified the patients into two groups was 0.54. RIT incidence was found to be significantly higher in the HPR ≤0.54 group than its HPR >0.54 counterpart(p < 0.001). Univariately T3‐4 stage, mean masticator apparatus dose>57.2Gy, and pre‐C‐CRT MMO ≤40.7 mm were found as the other significant correlates of increased RIT rates(p < 0.05). All four variables seemed to be independently connected to greater RIT incidence in multivariate analysis (p < 0.05, for each). Conclusion: The risk of post‐C‐CRT RIT may be significantly increased when pre‐treatment HPR levels are low. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
- Author
-
Topkan, Erkan, Selek, Ugur, Pehlivan, Berrin, Kucuk, Ahmet, Ozturk, Duriye, Ozdemir, Beyza Sirin, Besen, Ali Ayberk, and Mertsoylu, Huseyin
- Subjects
- *
LUNG cancer , *BIOMARKERS , *STATISTICS , *CONFIDENCE intervals , *NUTRITION , *INFLAMMATION , *MULTIVARIATE analysis , *IMMUNE system , *RETROSPECTIVE studies , *ACQUISITION of data , *CHEMORADIOTHERAPY , *TUMOR classification , *CANCER patients , *DESCRIPTIVE statistics , *MEDICAL records , *RECEIVER operating characteristic curves , *PROGRESSION-free survival , *SENSITIVITY & specificity (Statistics) , *LONGITUDINAL method , *OVERALL survival , *PROPORTIONAL hazards models - Abstract
Simple Summary: We investigated the prognostic significance of the newly created Global Immune-Nutrition-Inflammation Index (GINI) in IIIC non-small cell lung cancer (NSCLC) patients who received definitive concurrent chemoradiotherapy (CCRT). A total of 802 newly diagnosed stage IIIC NSCLC patients were included. The optimal pre-CCRT GINI cutoff was 1562 (area under the curve: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). GINI ≥ 1562 was associated with significantly shorter median locoregional progression-free (p < 0.001), progression-free (p < 0.001), and overall survival (p < 0.001) than GINI < 1562. For each survival endpoint, the association between GINI and survival outcomes appeared independent of other confounding variables (p < 0.05 for each). The novel GINI index effectively stratified patients with stage IIIC NSCLSC into two distinct subgroups, demonstrating significant differences in both median and long-term survival rates. Background: We sought to determine the prognostic value of the newly developed Global Immune-Nutrition-Inflammation Index (GINI) in patients with stage IIIC non-small cell lung cancer (NSCLC) who underwent definitive concurrent chemoradiotherapy (CCRT). Methods: This study was conducted on a cohort of 802 newly diagnosed stage IIIC NSCLC patients who underwent CCRT. The novel GINI created first here was defined as follows: GINI = [C-reactive protein × Platelets × Monocytes × Neutrophils] ÷ [Albumin × Lymphocytes]. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-CCRT GINI cut-off value that substantially interacts with the locoregional progression-free (LRPFS), progression-free (PFS), and overall survival (OS). Results: The optimal pre-CCRT GINI cutoff was 1562 (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). Patients presenting with a GINI ≥ 1562 had substantially shorter median LRPFS (13.3 vs. 18.4 months; p < 0.001), PFS (10.2 vs. 14.3 months; p < 0.001), and OS (19.1 vs. 37.8 months; p < 0.001) durations than those with a GINI < 1562. Results of the multivariate analysis revealed that the pre-CCRT GINI ≥ 1562 (vs. <1562), T4 tumor (vs. T3), and receiving only 1 cycle of concurrent chemotherapy (vs. 2–3 cycles) were the factors independently associated with poorer LRPS (p < 0.05 for each), PFS (p < 0.05 for each), and OS (p < 0.05 for each). Conclusion: The newly developed GINI index efficiently divided the stage IIIC NSCLSC patients into two subgroups with substantially different median and long-term survival outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients.
- Author
-
Yilmaz, Busra, Somay, Efsun, Topkan, Erkan, Pehlivan, Berrin, and Selek, Ugur
- Subjects
OSTEORADIONECROSIS ,NASOPHARYNX cancer ,CANCER patients ,HEMOGLOBINS ,DENTAL extraction ,CHEMORADIOTHERAPY - Abstract
Purpose: We aimed to determine whether pretreatment hemoglobin (Hb) levels can predict the risk of osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: ORN cases were identified from the records of LA-NPCs who had oral exams before and after CCRT. All Hb measurements were obtained on the first day of treatment. Receiving operating characteristic curve analysis was used to determine the relationship between Hb levels and ORN rates. The relationship between pretreatment Hb levels and ORN rates served as the primary endpoint, and secondary endpoints included the discovery of additional potential ORN risk factors. Results: Among the 263 eligible LA-NPCs, we identified 8.7% ORN cases. The ideal cutoff Hb before CCRT was 10.6 g/dL. It was revealed that HPR ≤ 10.6 group had a significantly higher ORN rate (32.5% vs. 1.5% for Hb > 10.6; P < 0.001). The mandibular V59.8 ≥ 36% Gy, pre-CCRT ≥ 4 tooth extractions, the presence of post-CCRT tooth extractions, and the time of post-CCRT tooth extractions > 8 months were the other factors associated with significantly increased ORN rates (P < 0.05 for each). Conclusion: Low pre-CCRT Hb levels appeared to be independently linked to significantly higher ORN rates. Pretreatment Hb levels may be used to establish preventive measures and predict ORN. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. The predictive value of pretreatment hemoglobin-to-platelet ratio on osteoradionecrosis incidence rates of locally advanced nasopharyngeal cancer patients managed with concurrent chemoradiotherapy.
- Author
-
Yilmaz, Busra, Somay, Efsun, Topkan, Erkan, Kucuk, Ahmet, Pehlivan, Berrin, and Selek, Ugur
- Subjects
NASOPHARYNX cancer ,HEMOGLOBINS ,PREDICTIVE tests ,ORAL hygiene ,BLOOD platelets ,OSTEORADIONECROSIS ,RETROSPECTIVE studies ,HEAD & neck cancer ,DISEASE incidence ,CHEMORADIOTHERAPY ,CANCER ,CANCER patients ,COMPARATIVE studies ,DESCRIPTIVE statistics ,NASOPHARYNX tumors ,LONGITUDINAL method ,DISEASE risk factors - Abstract
Background: This retrospective study aimed to investigate whether the pretreatment hemoglobin-to-platelet ratio (HPR) could predict the risk of osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (C-CRT) for locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: ORN cases were reported from the records of LA-NPC patients who had oral examinations before and after C-CRT. The pretreatment HPR values were calculated on the first day of C-CRT. The connection between HPR values and ORN occurrences was determined using receiver operating characteristic curve analysis. The primary endpoint was the relationship between the pretreatment HPR values and post-C-CRT ORN incidence rates, while secondary endpoints included the identification of other putative ORN risk factors. Results: We distinguished 10.9% incidences of ORN during the post-C-CRT follow-up period among 193 LA-NPC patients. The optimal cutoff for pre-C-CRT HPR was 0.48 that grouped the patients into two HPR groups with fundamentally different post-C-CRT ORN incidence rates: Group 1: HPR ≤ 0.48 (N = 60), and Group 2: HPR > 0.48 (N = 133). The comparative analysis indicated a significantly higher ORN incidence in HPR ≤ 0.48 group (30%; P < 0.001). The other factors associated with meaningfully increased ORN rates included the presence of pre-C-CRT ≥ 5 teeth extractions, mandibular volume receiving ≥ 64 Gy, post-C-CRT tooth extractions, mean mandibular dose ≥ 50.6 Gy, and C-CRT to tooth extraction interval > 5.5 months. Conclusion: Low pretreatment HPR levels were independently and unequivocally linked to significantly increased incidence of ORN post-C-CRT. Pre-C-CRT HPR levels may be used to estimate the incidence of ORN and be useful for taking preventive and therapeutic measures in these patients such as monitoring oral hygiene with strict follow-up, avoidance of unnecessary tooth extractions, particularly after C-CRT, and use of more rigorous mandibular RT dose limits. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy
- Author
-
Ozdemir, Yurday, Topkan, Erkan, Mertsoylu, Huseyin, Selek, Ugur, Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Özdemir, Yurday, Topkan, Erkan, Mertsoylu, Hüseyin, and School of Medicine
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Medicine ,Oncology ,survival results ,Gastroenterology ,chemoradiotherapy ,03 medical and health sciences ,0302 clinical medicine ,Prognostic nutritional index ,Non-small-cell lung carcinoma ,Prognosis ,Chemoradiotherapy ,Survival results ,Internal medicine ,non-small -cell lung carcinoma ,Carcinoma ,medicine ,Original Research ,Univariate analysis ,Chemotherapy ,Receiver operating characteristic ,business.industry ,Area under the curve ,prognostic nutritional index ,medicine.disease ,Confidence interval ,Radiation therapy ,030104 developmental biology ,Cancer Management and Research ,030220 oncology & carcinogenesis ,prognosis ,business - Abstract
Purpose: to investigate the prognostic utility of the prognostic nutritional index (PNI) in stage IIIB non-small-cell lung carcinoma (NSCLC) patients undergoing concurrent chemoradiotherapy (CRT). Methods: a total of 358 stage IIIB NSCLC patients who received a total dose of 60-66 Gy (2 Gy/fraction) radiotherapy and >= 1 cycle(s) of platinum-based chemotherapy were analyzed. The receiver operating curve analysis was utilized to identify the optimal PNI cut-off value demonstrating a significant connection with the overall survival (OS), locoregional progression-free survival (LRPFS), and progression-free survival (PFS). Results: at a median follow-up time of 22.5 months (range: 2.4-123.5), 30.2% and 14% of the patients were still alive and free of disease progression, respectively.The median OS, LRPFS, and PFS were 25.2 [95% confidence interval (CI): 36.3-46.6 months], 15.4 (95% CI: 26.6-35.3 months), and 10.7 (95% CI: 36.8-69.9 months), individually, for the whole study accomplice. The ROC analysis revealed an optimum rounded cut-off that associated meaningfully with each of the OS [area under the curve (AUC): 84.1%; sensitivity: 75.9%;72.4% specificity], LRPFS (AUC: 92.4%; sensitivity: 87.9%; 85.1% specificity), and PFS (AUC: 80.1%; sensitivity: 73.7%; 71.6% specificity) at a value of 40.5. Comparative analyses revealed that the patients presenting with PNI 40.5. In univariate analyses, lower T-stage (1-2 vs 3-4; P< 0.001), lower N-stage (N2 vs N3; P< 0.001), anemia status (absent vs present; P< 0.001), weight loss status (= 5%; P< 0.001), and PM group (40.5; P, NA
- Published
- 2020
29. Toxicities and prognostic factors in elderly HPV‐associated oropharyngeal cancer patients treated with radiotherapy or chemoradiotherapy.
- Author
-
Topkan, Erkan, Somay, Efsun, and Selek, Ugur
- Subjects
HEAD & neck cancer ,OROPHARYNGEAL cancer ,PROGNOSIS ,CANCER patients ,CHEMORADIOTHERAPY ,INTENSITY modulated radiotherapy - Abstract
This article discusses a study conducted on elderly patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) who underwent chemoradiotherapy (CRT). The study found that the 5-year progression-free survival (PFS), overall survival (OS), and local control (LC) rates were 57%, 52%, and 91%, respectively. The study also identified the Charlson Comorbidity Index (CCI) as a predictive factor for OS. However, the article points out that the study did not address certain late toxicities, such as radiation-induced trismus (RIT) and radiation-induced tooth loss (RITL), which can significantly impact patients' quality of life. Additionally, the article suggests that the small sample size and lack of data on salvage therapies may have influenced the study's results. Overall, the study provides valuable insights for clinicians and researchers working in head and neck oncology. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
30. Comment on "Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR). https://doi.org/10.1016/j.ejso.2023.107108.".
- Author
-
Topkan, Erkan, Somay, Efsun, and Selek, Ugur
- Subjects
CARCINOMA ,PARANASAL sinuses ,HEAD & neck cancer ,RETROSPECTIVE studies - Published
- 2024
- Full Text
- View/download PDF
31. Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy.
- Author
-
Yilmaz, Busra, Somay, Efsun, Selek, Ugur, and Topkan, Erkan
- Subjects
DENTAL extraction ,CHEMORADIOTHERAPY ,HEAD & neck cancer ,CANCER patients ,DENTAL caries ,RECEIVER operating characteristic curves ,SENSITIVITY & specificity (Statistics) - Abstract
Background: To evaluate the utility of pretreatment systemic immune-inflammation index (SII) in predicting the teeth caries and need for tooth extraction after concurrent chemoradiotherapy (C-CRT) for locally advanced squamous-cell head and neck cancer (LA-SCHNC) patients.Methods: The records of LA-SCHNC patients who underwent formal dental evaluations at pre- and post-C-CRT periods were retrospectively analyzed. The pretreatment SII values were calculated using the platelet, neutrophil, and lymphocyte measures acquired on the first day of C-CRT: SII=Platelets×neutrophils/lymphocytes. Receiver operating characteristic (ROC) curve analysis was employed to identify the ideal pre-C-CRT SII cutoff that may predict the teeth caries and the need for tooth extraction after the C-CRT. The primary endpoint was the link between the pre-C-CRT SII and the need for tooth extraction during the follow-up period.Results: A sum of 126 patients were included. Median follow-up was 4.9 years (range: 2.7-7.8). Nasopharyngeal and laryngeal cancers comprised the majority (75.4%) study cohort. Post-treatment teeth extractions were reported in 62.7% patients. The optimal cutoff was 558 [Area under the curve (AUC): %76.8 sensitivity: 72.3%; and specificity: 70.9%] that grouped the patients into two subgroups with significantly different post-C-CRT tooth extraction rates: Group 1: SII≤558 (n = 70) and SII>558 (n = 56), respectively. Correlation analysis revealed a significant relationship between the pretreatment SII and the tooth extraction rates after the C-CRT (rs:0.89: P = 0.001). The comparative analysis displayed that the teeth extractions rates were significantly higher in the SII>558 group (77.1% versus 51.4% for SII≤558; Hazard ratio: 1.68; P = 0.001). Further analyses showed that the pre-C-CRT SII>558 was the unique factor associated with meaningfully higher necessities for post-C-CRT teeth extractions.Conclusion: The present outcomes intimated that high pretreatment SII levels were linked to significantly increased post-treatment teeth extractions in LA-SCHNC patients undergoing definitive C-CRT. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
32. The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy.
- Author
-
Topkan, Erkan, Selek, Ugur, Pehlivan, Berrin, Kucuk, Ahmet, Haksoyler, Veysel, Durankus, Nulifer Kilic, Sezen, Duygu, and Bolukbasi, Yasemin
- Subjects
PANCREATIC cancer ,OVERALL survival ,RECEIVER operating characteristic curves ,CHEMORADIOTHERAPY ,SURVIVAL rate - Abstract
Purpose: We evaluated the prognostic quality of the novel pancreas cancer prognostic index (PCPI), a combination of CA 19-9 and systemic inflammation response index (SIRI), on the outcomes of locally advanced pancreas adenocarcinoma (LAPAC) patients who received concurrent chemoradiotherapy (C-CRT). Methods: This retrospective analysis covered 152 unresectable LAPAC patients treated from 2007 to 2019. Receiver operating characteristic (ROC) curve analysis was used to define ideal cutoff thresholds for the pretreatment CA 19-9 and SIRI measurements, individually. The associations between the PCPI groups and progression-free- (PFS) and overall survival (OS) comprised the respective primary and secondary endpoints. Results: The ROC curve analysis distinguished the respective rounded optimal cutoffs at 91 U/m/L (< versus ≥ 90) and 1.8 (< versus ≥ 1.8) for CA 19-9 and SIRI, arranging the study cohort into two significantly different survival groups for each, with resultant four likely groups: Group-1: CA 19-9< 90 U/m/L and SIRI< 1.8, Group-2: CA 19-9< 90 U/m/L but SIRI≥ 1.8, Group-3: CA 19-9≥ 90 U/m/L but SIRI< 1.8, and Group-4: CA 19-9≥ 90 U/m/L and SIRI≥ 1.8. Since the PFS (P=0.79) and OS (P=0.86) estimates of the groups 2 and 3 were statistically indistinct, we merged them as one group and created the novel three-tiered PCPI: PCPI-1: CA 19-9< 90 U/m/L and SIRI< 1.8, PCPI-2: CA 19-9< 90 U/m/L but SIRI≥ 1.8 or CA 19-9≥ 90 U/m/L but SIRI< 1.8, and PCPI-3: CA 19-9≥ 90 U/m/L and SIRI≥ 1.8, respectively. Comparative analyses unveiled that the PCPI-1 and PCPI-3 groups had the respective best and worst PFS (17.0 versus 7.5 versus 4.4 months; P< 0.001) and OS (26.1 versus 15.1 versus 7.4 months; P< 0.001) outcomes, while the PCPI-2 group posed in between. The multivariate analysis outcomes confirmed the novel three tired PCPI's independent prognostic significance on either of the PFS [HR: 5.38 (95% confidence interval (CI): 4.96-5.80); P< 0.001)] and OS [HR: 5.67 (95% CI: 5.19-6.15); P< 0.001] endpoints, separately. Conclusion: The new PCPI introduced here can be used as an independent and reliable prognostic indicator to divide LAPAC patients into three subgroups with discrete survival results. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
- Author
-
Topkan, Erkan, Yucel Ekici, Nur, Ozdemir, Yurday, Besen, Ali Ayberk, Mertsoylu, Huseyin, Sezer, Ahmet, and Selek, Ugur
- Subjects
CANCER patients ,CANCER relapse ,CISPLATIN ,MULTIVARIATE analysis ,NASOPHARYNX cancer ,SURVIVAL ,TREATMENT effectiveness ,RETROSPECTIVE studies ,RECEIVER operating characteristic curves ,DESCRIPTIVE statistics ,NUTRITIONAL status ,CHEMORADIOTHERAPY ,DISEASE risk factors - Abstract
Background: To retrospectively assess the impact of prognostic nutritional index (PNI) on survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with concurrent chemoradiotherapy (CCRT). Methods: This study incorporated 154 patients with LA-NPC who received exclusive cisplatinum-based CCRT. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of pretreatment PNI cutoffs influencing survival results. The primary end point was the interaction between the overall survival (OS) and PNI values, while cancer-specific survival (CSS) locoregional progression-free survival (LR-PFS), distant metastasis–free survival (DMFS), and PFS were the secondary end points. Results: A rounded PNI cutoff value of 51 was identified in ROC curve analyses to exhibit significant link with CSS, OS, DMFS, and PFS outcomes, but not LR-PFS. Patients grouping per PNI value (≥51 [N = 95] vs <51 [N = 49]) revealed that PNI < 51 group had significantly shorter median CSS (P <.001), OS (P <.001), DMFS (P <.001), and PFS (P <.001) times than the PNI ≥ 51 group, and the multivariate results confirmed the PNI < 51 as an independent predictor of poor outcomes for each end point (P <.05 for each). The unfavorable impact of the low PNI was also continued at 10-year time point with survival rates of 77.9% versus 42.4%, 73.6% versus 33.9%, 57.9% versus 27.1%, and 52.6% versus 23.7% for CSS, OS, DMFS, and PFS, respectively. Additionally, we found that PNI < 51 was significantly associated with higher rates of weight loss >5% over past 6 months (49.2% versus 11.6%; P =.002) compared to PNI < 51 group. Conclusion: Low pre-CCRT PNI levels were independently associated with significantly reduced CSS, OS, DMFS, and PFS outcomes in patients with LA-NPC treated with definitive CCRT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
- Author
-
Kucuk, Ahmet, Ozkan, Emine Elif, Eskici Oztep, Sukran, Mertsoylu, Huseyin, Pehlivan, Berrin, Selek, Ugur, and Topkan, Erkan
- Subjects
SURVIVAL analysis (Biometry) ,LUNG cancer ,CANCER patients ,RECEIVER operating characteristic curves ,CHEMORADIOTHERAPY - Abstract
Background. Recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT). Patients and Methods. Present multi-institutional retrospective analysis incorporated LS-SCLC patients treated with CRT at three academic radiation oncology centers between January 2007 and December 2018. The SIRI was calculated by using the peripheral blood neutrophil (N), monocyte (M), and lymphocyte (L) counts acquired in the last ≤7 days before the commencement of the CRT: SIRI = N × M/L. Accessibility of pretreatment SIRI cutoff that may stratify the study population into two gatherings with distinctive overall survival (OS) results was evaluated by utilizing the receiver operating characteristic (ROC) curve analysis. Primary objective was the association between the SIRI values and the OS results. Results. Search for the availability of an ideal SIRI cutoff that may stratify the entire patients' population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 (N = 71) and Group 2: SIRI ≥1.93 (N = 110), respectively. At a median follow-up of 17.9 (95% CI: 13.2–22.6) months, 47 (26.0%) patients were still alive (47.9% for SIRI <1.93 versus 18.3% for SIRI ≥1.93; p < 0.001). Kaplan–Meier comparisons between the two SIRI groups showed that the SIRI <1.93 cohort had significantly longer median OS (40.5 versus 14.2 months; p < 0.001) than the SIRI ≥1.93 cohort. Similarly, the 3- (54% versus 12.6%) and 5-year (33% versus 9.9%) OS rates were also numerically superior in the SIRI <1.93 cohort. Results of the multivariate analyses uncovered that the prognostic significance of the SIRI on OS outcomes was independent of the other confounding variables. Conclusions. The results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy.
- Author
-
Topkan, Erkan, Ozdemir, Yurday, Kucuk, Ahmet, Guler, Ozan Cem, Sezer, Ahmet, Besen, Ali Ayberk, Mertsoylu, Huseyin, Senyurek, Sukran, Kilic Durankus, Nulifer, Bolukbasi, Yasemin, Selek, Ugur, and Pehlivan, Berrin
- Subjects
- *
PNEUMONIA , *LUNG cancer , *RECEIVER operating characteristic curves , *TUMOR classification , *CHEMORADIOTHERAPY ,NASOPHARYNX tumors - Abstract
Purpose. We aimed to retrospectively investigate the prognostic worth of pretreatment advanced lung cancer inflammation index (ALI) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradiotherapy (C-CRT). Patients and Methods. A total of 164 LA-NPC patients treated with cisplatinum-based definitive C-CRT were included in this retrospective cohort analysis. The convenience of ideal pre-C-CRT ALI cut-offs affecting survival results was searched by employing the receiver operating characteristic (ROC) curve analyses. The primary endpoint was the link between the ALI groups and overall survival (OS), while cancer-specific survival (CSS), locoregional progression-free survival [LR(PFS)], distant metastasis-free survival (DMFS), and PFS comprised the secondary endpoints. Results. The ROC curve analyses distinguished a rounded ALI cut-off score of 24.2 that arranged the patients into two cohorts [ALI ≥ 24.2 (N = 94) versus < 24.2 (N = 70)] with significantly distinct CSS, OS, DMFS, and PFS outcomes, except for the LRPFS. At a median follow-up time of 79.2 months (range: 6–141), the comparative analyses showed that ALI < 24.2 cohort had significantly shorter median CSS, OS, DMFS, and PFS time than the ALI ≥ 24.2 cohort (P < 0.001 for each), which retained significance at 5- (P < 0.001) and 10-year (P < 0.001) time points. In multivariate analyses, ALI < 24.2 was asserted to be an independent predictor of the worse prognosis for each endpoint (P < 0.001 for each) in addition to the tumor stage (T-stage) (P < 0.05 for all endpoints) and nodal stage (N-stage) (P < 0.05 for all endpoints). Conclusion. As a novel prognostic index, the pretreatment ALI < 24.2 appeared to be strongly associated with significantly diminished survival outcomes in LA-NPC patients treated with C-CRT independent of the universally recognized T- and N-stages. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study.
- Author
-
Topkan, Erkan, Ozdemir, Yurday, Guler, Ozan Cem, Kucuk, Ahmet, Besen, Ali Ayberk, Mertsoylu, Huseyin, Sezen, Duygu, Akdemir, Eyub Yasar, Sezer, Ahmet, Bolukbasi, Yasemin, Pehlivan, Berrin, and Selek, Ugur
- Subjects
- *
NON-small-cell lung carcinoma , *PROPENSITY score matching , *CHEMORADIOTHERAPY , *PROGRESSION-free survival , *CONFOUNDING variables - Abstract
Background. We retrospectively compared the incidence of isolated elective nodal failure (IENF) and toxicity rates and survival outcomes after elective nodal irradiation (ENI) versus involved-field RT (IFRT) by employing the propensity score matching (PSM) methodology in stage IIIB/C inoperable non-small-cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT). Methods. Our PSM examination included 1048 stage IIIB/C NSCLC patients treated with C-CRT from January 2007 to December 2016: a total dose of 66 Gy (2 Gy/fraction) radiotherapy and 1–3 cycles of platinum-based doublet chemotherapy concurrently. The primary and secondary endpoints were the IENF and toxicity rates and survival outcomes after ENI versus IFRT, respectively. Propensity scores were calculated for each group to adjust for confounding variables and facilitate well-balanced comparability by creating 1 : 1 matched study groups. Results. The median follow-up was 26.4 months for the whole study accomplice. The PSM analysis unveiled 1 : 1 matched 646 patients for the ENI (N = 323) and IFRT (N = 323) cohorts. Intergroup comparisons discovered that the 5-year isolated ENF incidence rates (3.4% versus 4.3%; P = 0.52) and median overall survival (25.2 versus 24.6 months; P = 0.69), locoregional progression-free survival (15.3 versus 15.1 months; P = 0.52), and progression-free survival (11.7 versus 11.2 months; P = 0.57) durations were similar between the ENI and IFRT cohorts, separately. However, acute grade 3-4 leukopenia (P = 0.0012), grade 3 nausea-vomiting (P = 0.006), esophagitis (P = 0.003), pneumonitis (P = 0.002), late grade 3-4 esophageal toxicity (P = 0.038), and the need for hospitalization (P < 0.001) were all significantly higher in the ENI than in the IFRT group, respectively. Conclusion. Results of the present large-scale PSM cohort established the absence of meaningful IENF or survival differences between the IFRT and ENI cohorts and, consequently, counseled the IFRT as the elected RT technique for such patients since ENI increased the toxicity rates. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
- Author
-
Topkan, Erkan, Mertsoylu, Huseyin, Kucuk, Ahmet, Besen, Ali Ayberk, Sezer, Ahmet, Sezen, Duygu, Bolukbasi, Yasemin, Selek, Ugur, and Pehlivan, Berrin
- Subjects
- *
RECEIVER operating characteristic curves , *CHEMORADIOTHERAPY , *LYMPHOCYTE count , *PROGRESSION-free survival , *MULTIVARIATE analysis - Abstract
Background. We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Methods. Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI = neutrophil × monocyte / lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results. Results. The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N = 58) had significantly superior median PFS (13.8 versus 6.7 months; P < 0.001) and OS (28.6 versus 12.6 months; P < 0.001) lengths than SIRI ≥1.6 patients (N = 96), respectively. Although the N0 (versus N1; P < 0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P < 0.001 for each). Conclusion. Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy.
- Author
-
Topkan, Erkan, Mertsoylu, Huseyin, Ozdemir, Yurday, Sezer, Ahmet, Kucuk, Ahmet, Besen, Ali Ayberk, Ozyilkan, Ozgur, and Selek, Ugur
- Subjects
LUNG cancer ,PNEUMONIA ,CHEMORADIOTHERAPY ,RECEIVER operating characteristic curves ,CARCINOMA - Abstract
Background/Aims: Previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treated with concurrent chemoradiotherapy (CCRT). Hence, we aimed to investigate the prognostic value of pre-treatment ALI in LAPC patients who underwent radical CCRT. Methods: Present retrospective cohort analysis incorporated 141 LAPC patients who received radical CCRT. Accessibility of baseline ALI cutoff(s) impacting survival outcomes was sought by receiver operating characteristic (ROC) curve analysis. Interaction between the ALI and overall- (OS) and progression-free survival (PFS) comprised our primary and secondary endpoints, respectively. Results: At a median follow-up of 14.4 months (range: 3.2–74.2), the median PFS and OS were 7.5 (%95 CI: 5.9–9.1) and 14.6 months (%95 CI: 11.6–17.6), respectively. ROC curve analyses set the ideal ALI cutoff value at 25.3 (AUC: 75.6%; sensitivity: 72.7%; specificity: 70.3%) that exhibited significant associations with both the OS and PFS results. Patient stratification into two groups per ALI [≤25.3 (N=75) versus>25.3 (N=66)] showed that the ALI>25.3 group had significantly superior median OS (25.8 versus 11.4 months; P<0.001) and PFS (15.9 versus 6.0 months; P<0.001) durations than its ALI≤25.3 counterpart. Other factors exhibiting significantly better OS and PFS rates were N
0 stage (versus N1; P<0.05 for each endpoint) and CA 19-9 ≤90 U/mL (versus >90 U/mL; P<0.05 for each endpoint), respectively. These three factors were additionally asserted to be independent indicators of longer OS (P<0.05 for each) and PFS (P<0.05 for each) in multivariate analyses. Conclusion: Results of this hypothesis-generating research proposed the pre-CCRT ALI as a novel robust associate of OS and PFS outcomes for LAPC patients undergoing CCRT. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
39. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients.
- Author
-
Topkan, Erkan, Selek, Ugur, Ozdemir, Yurday, Besen, Ali A., Guler, Ozan C., Yildirim, Berna A., Mertsoylu, Huseyin, Findikcioglu, Alper, Ozyilkan, Ozgur, and Pehlivan, Berrin
- Subjects
- *
CHEMORADIOTHERAPY , *SQUAMOUS cell carcinoma , *HEMORRHAGE , *TUMORS ,PULMONARY artery diseases - Abstract
We aimed to identify the fatal pulmonary hemorrhage- (FPH-) related risk factors in stage 3B/C squamous-cell lung carcinoma (SqCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT). Medical records of 505 stage 3B/C SqCLC patients who underwent 66 Gy radiotherapy plus 1-3 cycles of concurrent chemotherapy with available pretreatment thoracic computerized tomography scans were retrospectively analyzed. Primary end-point was the identification of FPH-related risk factors. Examined factors included the basal patient and tumor characteristics with specific emphasis on the tumor cavitation (TC) status, tumor size (TS) and cavitation size (CS), tumor volume and cavitation volume (TV and CV), relative cavitation size (RCS = CS/TS), and relative cavitation volume (RCV=CV/TV). FPH emerged in 13 (2.6%) patients, with 12 (92.3%) of them being diagnosed ≤12 months of C-CRT. All FPHs were diagnosed in patients with TC (N=60): group-specific FPH incidence: 21.6%. TC (P<0.001) was the unique independent factor associated with higher FPH risk in multivariate analysis. Further analysis limited to TC patients exhibited the RCV>0.14 (37.5% versus 11.1% for RCV≤0.14; P<0.001), major RCS group [31.0% versus 19.0% for minor versus 0% for minimum RCS; P=0.008), and baseline hemoptysis (26.3% versus 13.6% for no hemoptysis; P=0.009) as the independent risk factors for higher FPH incidence. FPH was an infrequent (2.6%) complication of C-CRT in stage 3B/C SqCLC patients, but its incidence increased to 37.5% in patients presenting with TC and RCV>0.14. Diagnosis of >90% FPHs ≤12 months of C-CRT stresses the importance of close and careful follow-up of high-risk patients after C-CRT for multidisciplinary discussion of possible invasive preventive measures. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Preoperatif kemoradyoterapi uygulanan lokal ileri rektum kanserli hastalarda tedavi öncesi hemoglobin düzeyinin prognostik rolü.
- Author
-
Yıldırım, Berna Akkuş, Sümbül, Ahmet Taner, Güler, Ozan Cem, Sedef, Ali Murat, Önal, Cem, and Topkan, Erkan
- Abstract
Copyright of Cukurova Medical Journal / Çukurova Üniversitesi Tip Fakültesi Dergisi is the property of Cukurova University, Faculty of Medicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
41. Octreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal Carcinoma.
- Author
-
Topkan, Erkan and Karaoglu, Aziz
- Subjects
- *
DIARRHEA , *LOPERAMIDE , *CANCER patients , *RADIOTHERAPY , *OCTREOTIDE acetate - Abstract
Objective: To evaluate the efficacy of octreotide in the treatment of chemoradiotherapy (CRT)-induced diarrhea (CRTID) refractory to conventional loperamide treatment in this pilot study. Methods: Forty-two rectal carcinoma (T3–4N0–2M0) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide. Eligible patients were treated with pelvic radiotherapy combined with bolus 5- fluorouracil CRT. Octreotide was administered subcutaneously, 150 μg three times daily, for 5 consecutive days. Only complete resolution of diarrhea was considered as therapeutic success. Results: Diarrhea mainly occurred in the first 4 weeks of CRT (83.3%) and completely resolved in 34 patients (80.9%) following octreotide administration. Mean time to response was 2.7 days: 27 patients (64%) responded during the first 3 days, and the remaining 7 (17%) on days 4 and 5. No significant side effect was reported. Eight patients (19.1%) with refractory diarrhea were hospitalized for additional treatment. No treatment delay was reported in complete responders, whereas an average 7.7-day delay was observed in refractory patients. Antidiarrheal treatment was administered on an outpatient basis in the response group, whereas refractory patients were hospitalized for an average of 8.8 days. Conclusion: Daily subcutaneous octreotide administration (150 μg t.i.d.) for 5 days is apparently an effective, tolerable treatment modality for concurrent CRTID refractory to loperamide. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
42. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy
- Author
-
Huseyin Mertsoylu, Erkan Topkan, Ozgur Ozyilkan, Ahmet Kucuk, Yurday Ozdemir, Ali Ayberk Besen, Ahmet Sezer, Ugur Selek, Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Topkan, Erkan, Mertsoylu, Hüseyin, Özdemir, Yurday, Sezer, Ahmet, Küçük, Ahmet, Besen, Ali Ayberk, Özyılkan, Özgür, School of Medicine, and Department of Radiation Oncology
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Multivariate analysis ,survival outcomes ,Locally advanced ,Inflammation ,Gastroenterology ,locally-advanced pancreas cancer ,advanced lung cancer inflammation index ,concurrent chemoradiotherapy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Lung cancer ,Original Research ,Receiver operating characteristic ,business.industry ,Retrospective cohort study ,medicine.disease ,Locally-advanced pancreas cancer ,Advanced lung cancer inflammation index ,Concurrent chemoradiotherapy ,Prognosis ,Survival outcomes ,030104 developmental biology ,Oncology ,Cancer Management and Research ,030220 oncology & carcinogenesis ,prognosis ,medicine.symptom ,business ,Chemoradiotherapy - Abstract
Background/Aims: previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treated with concurrent chemoradiotherapy (CCRT). Hence, we aimed to investigate the prognostic value of pre-treatment ALI in LAPC patients who underwent radical CCRT. Methods: present retrospective cohort analysis incorporated 141 LAPC patients who received radical CCRT. Accessibility of baseline ALI cutoff(s) impacting survival outcomes was sought by receiver operating characteristic (ROC) curve analysis. Interaction between the ALI and overall- (OS) and progression-free survival (PFS) comprised our primary and secondary endpoints, respectively. Results: at a median follow-up of 14.4 months (range: 3.2-74.2), the median PFS and OS were 7.5 (%95 CI: 5.9-9.1) and 14.6 months (%95 CI: 11.6-17.6), respectively. ROC curve analyses set the ideal ALI cutoff value at 25.3 (AUC: 75.6%; sensitivity: 72.7%; specificity: 70.3%) that exhibited significant associations with both the OS and PFS results. Patient stratification into two groups per ALI [25.3 (N=66)] showed that the ALI>25.3 group had significantly superior median OS (25.8 versus 11.4 months; P90 U/mL; P, NA
- Published
- 2019
43. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients
- Author
-
Huseyin Mertsoylu, Yurday Ozdemir, Ahmet Kucuk, Ahmet Sezer, Erkan Topkan, Ugur Selek, Ali Ayberk Besen, Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Topkan, Erkan, Özdemir, Yurday, Küçük, Ahmet, Besen, Ali Ayberk, Mertsoylu, Hüseyin, Sezer, Ahmet, School of Medicine, and Department of Radiation Oncology
- Subjects
Male ,Multivariate analysis ,Cancer Treatment ,Toxicology ,Pathology and Laboratory Medicine ,Gastroenterology ,Lung and Intrathoracic Tumors ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,Medicine and Health Sciences ,030212 general & internal medicine ,Science and technology ,Multidisciplinary ,Pharmaceutics ,Area under the curve ,Chemoradiotherapy ,Middle Aged ,Progression-Free Survival ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Medicine ,Treatment time ,Radiation-therapy ,Local-control ,Phase-III ,Sequential chemoradiotherapy ,Retrospective analysis ,Thoracic radiotherapy ,Chemotherapy worth ,Advanced head ,Cancer ,Female ,Research Article ,Adult ,Clinical Oncology ,medicine.medical_specialty ,Science ,Radiation Therapy ,03 medical and health sciences ,Cancer Chemotherapy ,Drug Therapy ,Internal medicine ,medicine ,Carcinoma ,Humans ,Chemotherapy ,Progression-free survival ,Aged ,Neoplasm Staging ,Receiver operating characteristic ,Toxicity ,business.industry ,Proportional hazards model ,Biology and Life Sciences ,Cancers and Neoplasms ,medicine.disease ,Non-Small Cell Lung Cancer ,Lymph Nodes ,Clinical Medicine ,business ,Combination Chemotherapy - Abstract
Background: to investigate the detrimental effects of prolonged overall radiotherapy duration (ORTD) on survival outcomes of stage IIIB/C NSCLC patients treated with concurrent chemoradiotherapy (C-CRT) Methods: the study cohort consisted of 956 patients who underwent C-CRT for stage IIIB/C NSCLC. Primary endpoint was the association between the ORTD and overall survival (OS) with locoregional progression-free survival (LRPFS) and PFS comprising the secondary endpoints. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of the cut-off that interacts with survival outcomes. Multivariate Cox model was utilized to identify the independent associates of survival outcomes. Results: the ROC curve analysis exhibited significance at 49 days of ORTD cut-off that dichotomized patients into ORTD, NA
- Published
- 2019
44. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy
- Author
-
Huseyin Mertsoylu, Erkan Topkan, Yurday Ozdemir, Duygu Sezen, Berna Akkus Yildirim, Nur Yücel Ekici, Ali Ayberk Besen, Ugur Selek, Sezen, Duygu, Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Topkan, Erkan, Ekici, Nur Yücel, Özdemir, Yurday, Besen, Ali Ayberk, Yıldırım, Berna Akkuş, Mertsoylu, Hüseyin, School of Medicine, and Department of Radiation Oncology
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Anemia ,Clinical Biochemistry ,Hemoglobin levels ,Cancer nasopharynx ,Gastroenterology ,Pathology and Forensic Medicine ,Hemoglobins ,Young Adult ,Internal medicine ,Humans ,Medicine ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Nasopharyngeal Neoplasms ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Concurrent chemoradiotherapy ,Survival Rate ,Treatment Outcome ,Oncology ,Nasopharyngeal carcinoma ,Biotechnology and applied microbiology ,Carcinoma, Squamous Cell ,Female ,Hemoglobin ,Prognosis ,business ,Value (mathematics) ,Follow-Up Studies - Abstract
Background: to retrospectively investigate the influence of pretreatment anemia and hemoglobin levels on the survival of nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy (C-CRT). Methods: a total of 149 nasopharyngeal carcinoma patients who received C-CRT were included. All patients had received 70 Gy to the primary tumor plus the involved lymph nodes, and 59.4 Gy and 54 Gy to the intermediate- and low-risk neck regions concurrent with 1-3 cycles of cisplatin. Patients were dichotomized into non-anemic and anemic (hemoglobin, NA
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.